Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other financing activities (2016 - 2024)

Kiora Pharmaceuticals (KPRX) has disclosed Other financing activities for 8 consecutive years, with -$1136.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Other financing activities fell 100.18% year-over-year to -$1136.0, compared with a TTM value of -$1136.0 through Mar 2025, down 100.06%, and an annual FY2024 reading of $1.2 million, up 63.24% over the prior year.
  • Other financing activities was -$1136.0 for Q2 2024 at Kiora Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $1.2 million in Q1 2024 and bottomed at -$1136.0 in Q2 2024.
  • Average Other financing activities over 3 years is $402962.3, with a median of $291241.0 recorded in 2020.
  • Peak annual rise in Other financing activities hit 1313.28% in 2024, while the deepest fall reached 100.18% in 2024.
  • Year by year, Other financing activities stood at $498197.0 in 2020, then increased by 29.42% to $644753.0 in 2023, then plummeted by 100.18% to -$1136.0 in 2024.
  • Business Quant data shows Other financing activities for KPRX at -$1136.0 in Q2 2024, $1.2 million in Q1 2024, and $644753.0 in Q2 2023.